Trial Search Results

A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)

The purpose of this study is to determine which patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Clovis Oncology, Inc.

Collaborator: Myriad Genetics, Inc.

Stanford Investigator(s):

Intervention(s):

  • Drug: Oral rucaparib

Phase:

Phase 2

Eligibility


The following eligibility criteria pertain to patients enrolling into PART 2 of the study:

Inclusion:

   - Have a histologically confirmed diagnosis of high grade serous or Grade 2 or Grade 3
   endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer

   - Received at least 3 prior chemotherapy regimens. Non-chemotherapy regimens and
   maintenance therapies administered as single agent treatment will not count as a
   chemotherapy regimen

   - Relapsed/progressive disease as confirmed by CT scan

   - Have biopsiable and measurable disease. Note: biopsy is optional for patients known to
   harbor a deleterious gBRCA mutation

   - Have sufficient archival formalin-fixed paraffin-embedded (FFPE) tumor tissue
   available for planned analyses

Exclusion:

   - History of prior cancers except for those that have been curatively treated, with no
   evidence of cancer currently (provided all chemotherapy was completed >6 months prior
   and/or bone marrow transplant >2 years prior to first dose of rucaparib).

   - Prior treatment with any PARP inhibitor

   - Symptomatic and/or untreated central nervous system metastases

   - Pre-existing duodenal stent and/or any other gastrointestinal disorder or defect that
   would, in the opinion of the Investigator, interfere with absorption of rucaparib

   - Hospitalization for bowel obstruction within 3 months prior to enrollment

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

Female

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office
650-498-7061
Not Recruiting